Guidelines for high-flow nasal cannula oxygen therapy in neonates (2022)
© 2023 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd..
High-flow nasal cannula (HFNC) oxygen therapy, which is important in noninvasive respiratory support, is increasingly being used in critically ill neonates with respiratory failure because it is comfortable, easy to setup, and has a low incidence of nasal trauma. The advantages, indications, and risks of HFNC have been the focus of research in recent years, resulting in the development of the application. Based on current evidence, we developed guidelines for HFNC in neonates using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). The guidelines were formulated after extensive consultations with neonatologists, respiratory therapists, nurse specialists, and evidence-based medicine experts. We have proposed 24 recommendations for 9 key questions. The guidelines aim to be a source of evidence and reference of HFNC oxygen therapy in clinical practice, and so that more neonates and their families will benefit from HFNC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of evidence-based medicine - 16(2023), 3 vom: 06. Sept., Seite 394-413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Guidelines |
|---|
| Anmerkungen: |
Date Completed 05.10.2023 Date Revised 05.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jebm.12546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361719507 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361719507 | ||
| 003 | DE-627 | ||
| 005 | 20231226085733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jebm.12546 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361719507 | ||
| 035 | |a (NLM)37674304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines for high-flow nasal cannula oxygen therapy in neonates (2022) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2023 | ||
| 500 | |a Date Revised 05.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a High-flow nasal cannula (HFNC) oxygen therapy, which is important in noninvasive respiratory support, is increasingly being used in critically ill neonates with respiratory failure because it is comfortable, easy to setup, and has a low incidence of nasal trauma. The advantages, indications, and risks of HFNC have been the focus of research in recent years, resulting in the development of the application. Based on current evidence, we developed guidelines for HFNC in neonates using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). The guidelines were formulated after extensive consultations with neonatologists, respiratory therapists, nurse specialists, and evidence-based medicine experts. We have proposed 24 recommendations for 9 key questions. The guidelines aim to be a source of evidence and reference of HFNC oxygen therapy in clinical practice, and so that more neonates and their families will benefit from HFNC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a high-flow | |
| 650 | 4 | |a infant, newborn | |
| 650 | 4 | |a nasal cannula | |
| 650 | 4 | |a oxygen inhalation therapy | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 700 | 1 | |a Zhao, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Xintian |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Keren |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Zhenlang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Zhichun |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Dezhi |e verfasserin |4 aut | |
| 700 | 0 | |a Evidence-Based Medicine Group, Neonatologist Society, Chinese Medical Doctor Association |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of evidence-based medicine |d 2008 |g 16(2023), 3 vom: 06. Sept., Seite 394-413 |w (DE-627)NLM206067801 |x 1756-5391 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:3 |g day:06 |g month:09 |g pages:394-413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jebm.12546 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 3 |b 06 |c 09 |h 394-413 | ||